Results 31 to 40 of about 19,015 (246)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study

Medicines, 2022
Background and Objectives: This study aimed to investigate the changes in obesity severity, glucose metabolism, and body composition in patients with obesity and type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP1-RA ...
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata   +7 more
doaj   +1 more source

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Frontiers in Endocrinology, 2021
Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective
Juris J. Meier
doaj   +1 more source

Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]

, 2018
Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A, Caplan, Liron, Grunwald, Gary K, Liu, Wenhui G, Maddox, Thomas M, Raghavan, Sridharan, Reusch, Jane E.B, Saxon, David R   +7 more
core   +3 more sources

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes:a contemporary analysis [PDF]

, 2018
Aims: To describe the prevalence of major cardiovascular disease (CVD) and risk factor control in a contemporary population with Type 2 diabetes.Methods: We used data from the national registry in Scotland, Scottish Care Information-Diabetes, linked to ...
Blackbourn, L. A. K., Colhoun, H. M., McCrimmon, R. J., McGurnaghan, S., Mocevic, E., Panton, U. Haagen, Sattar, N., Wild, S.   +7 more
core   +4 more sources

Incident ischaemic stroke and Type 2 diabetes:trends in incidence and case fatality in Scotland 2004-2013 [PDF]

, 2017
Aim: To describe trends in first ischaemic stroke incidence and case fatality in adults with and without a diagnosis of Type 2 diabetes prior to their ischaemic stroke event in Scotland between 2004 and 2013.
Anwar, Brown, Chen, Go, Gouni-Berthold, Gregg, Guthrie, Hotchkiss, Howard, Kautzky-Willer, Kernan, Krishnamurthi, Logue, Looker, Marso, Mulnier, Paul, Peters, Peters, Read, Regensteiner, Rossi, Shah, Turner, Vamos, Wannamethee, Winston, Zhao   +27 more
core   +3 more sources

Semaglutide [PDF]

Reactions Weekly, 2022
Agostino Milluzzo, Laura Sciacca
  +5 more sources

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Frontiers in Endocrinology
BackgroundWithdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. There are some studies implying that metformin might attenuate weight regain.
Mojca Jensterle, Mojca Jensterle, Simona Ferjan, Simona Ferjan, Andrej Janez, Andrej Janez   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients

Metabolites, 2022
We evaluated time-course changes and the relationship between eating behavior and glycemic profile during the treatment of 34 obese type 2 diabetic patients with the glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide.
Takayuki Masaki, Yoshinori Ozeki, Yuichi Yoshida, Mitsuhiro Okamoto, Shotaro Miyamoto, Koro Gotoh, Hirotaka Shibata   +6 more
doaj   +1 more source

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

, 2017
AIM: To investigate the mechanism of action for body weight loss with semaglutide. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks treatment with once-weekly ...
Axelsen, MB, Blundell, J, Finlayson, G, Flint, A, Gibbons, C, Hjerpsted, J, Kvist, T   +6 more
core   +1 more source